DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Elotuzumab
Elotuzumab
= 'NH., Diseases, Central Nerrous System M)Ury and Different Foims of Mflannnation
Management of Multiple Myeloma: the Changing Paradigm
Multiple Myeloma
Elotuzumab (Empliciti®) Horizons Infosheet Clinical Trials and Novel Drugs
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
Immunotherapies Shape the Treatment Landscape for Hematologic Malignancies Jane De Lartigue, Phd
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
Sarclisa, INN-Isatuximab
Chemotherapy: Drugs E-O Policy (Chemo Drug E-O)
Monoclonal Antibody-Based Therapy As a New Treatment Strategy in Multiple Myeloma
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Obinutuzumab Controls Growth of Slow-Growing Non
Clinical Applications of Newly Approved Drugs
Monoclonal Antibodies for the Treatment of Multiple Myeloma: an Update
Immune Therapies for Hematologic Malignancies
HPHC Utilization Management Review Criteria 6.16.2020
Auspar Attachment 2: Extract from the Clinical Evaluation Report for Elotuzumab
WO 2019/038250 Al 28 February 2019 (28.02.2019) W P O PCT
Top View
Australian Public Assessment Report for Elotuzumab
Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA
View of This Manuscript
Injectable and Health Care Administered Oncology Medical Drug Criteria Through Preferred (Optional)
INN Working Document 05.179 Update 2011
Oncology Dose Reduction Program Beginning July 1, 2021
Injectable Anti-Cancer Medications
A Mechanism of Resistance to Antibody-Targeted Immune Attack Dalal S
Prophylaxis Guidelines for the Adult Hematology Patient
(INN) for Biological and Biotechnological Substances
June 1, 2021 Dear Prevea360 Health Plan Provider
NEW YORK Provider Communications
5.01.540 (Effective Nov. 5, 2021) Miscellaneous Oncology Drugs
PDF of Antibody News
Mab) and Antibody Drug Conjugate (ADC
Cardiotoxicity of Novel Targeted Hematological Therapies
Therapeutic Advances in Oncology
Empliciti™ (Elotuzumab)
Oncology™ in 2017
FDA Approval for Vectibix & Companion Diagnostic
Empliciti, INN-Elotuzumab
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Oncology Medications Policy (1403)
Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment MAURIEN D
Emetogenic Potential of Antineoplastic Agents
Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
VIRGINIA Provider Communications
Oncology Therapy for the Generalist
EMPLICITI Safely None (4) and Effectively
Elotuzumab Enhances Natural Killer Cell Activation and Myeloma Cell Killing Through Interleukin-2 and TNF-Α Pathways
Bristol-Myers Squibb -- Barclays Global Healthcare Conference
Elotuzumab (Empliciti®) Office Administration Outpatient Facility Administration Infusion Center Administration
Jco374newview 1..1
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
A Phase 2 Study of Isatuximab Monotherapy in Patients With
Drug Class Prior Authorization Criteria Antineoplastic Agents
Why Immunotherapy Fails in Multiple Myeloma
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma Tatiana Pazina1,2, Ashley M
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
Crizanlizumab-Tmca
(INN) for Biological and Biotechnological Substances
Generic (Brand) Name Mechanism of Action Mechanism of Action
Download Slides for Episode 1
Chemo Agents for Specific Cancers
A Review of Newly Approved Antineoplastic Medications - 2015 LISA NARVESON, PHARM D ASSISTANT PROFESSOR of PRACTICE NORTH DAKOTA STATE UNIVERSITY Acknowledgements
Elotuzumab - Drugbank
Monoclonal Antibodies in Cancer Therapy
Phase Ib Trial of Obinutuzumab in Combination with Induction Chemotherapy Followed by Obinutuzumab Maintenance in FL
Elotuzumab (Empliciti)
Elotuzumab (Empliciti®) Prior Authorization Drug Coverage Policy
NK Cells in the Treatment of Hematological Malignancies
Assessment of the Evolution of Cancer Treatment Therapies
Results of a Phase 1 Trial of GDA-201, Nicotinamide-Expanded
EMPLICITI for These Highlights Do Not Include All the Information Needed to Use Grade 2 Or Higher and Permanently Discontinue for Severe Infusion Reaction
Diplomat Specialty Pipeline Report
761113Orig1s000
Adjuvant Tkis
A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings
Empliciti® (Elotuzumab)
Current Antibody-Based Therapies for the Treatment of Multiple Myeloma